Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 185

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 185
---
 all.

If sufficient
investment cannot be obtained, the Company may need to implement cost-cutting measures, scale back its R&D activities, or delay certain
development programs. Despite these potential challenges, management and the board of directors believe that the Company’s existing
financial resources will be sufficient to sustain its planned operations for at least the next twelve months.

The consolidated
financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts
and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

<div align='center'>F-8</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 1 – GENERAL (Cont.)

To date, Predecessor
has not generated any revenue from its current operations and therefore is dependent upon external sources for financing its operations.
As of July 23, 2024, and December 31, 2023, the Predecessor had an accumulated deficit of $3,343 and $1,922, respectively Furthermore,
the Company intends to continue to finance the operating activities of the Predecessor by raising capital. As of December 31, 2023, the
Predecessor has raised approximately $3,109. The Successor has declared it will continue financing Predecessor’s activity. If the Predecessor
will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may
be required to implement a cost reduction and/or delay part of its development programs.

| c. | Impact of the “Iron Swords” War on Israel: |

In October
2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and
military targets. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against
Hamas and other terrorist organizations in parallel to their continued rocket and terror attacks. In addition, Hezbollah have attacked
military and civilian targets in Northern Israel, to which Israel has responded, including through increased air and ground operations
in Lebanon. Since the war broke out, our subsidiary’s operations have not been adversely affected by this situation, and we have not experienced
disruptions to our development activities. However, the intensity and duration of Israel’s current war against Hamas and Hezbollah
is difficult to predict at this stage, as are such war’s economic implications on the Company